NCT02028767View on ClinicalTrials.gov

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Healthy
Interventions
DRUG

Empagliflozin 2.5 mg

Empagliflozin 2.5 mg tablet

DRUG

Empagliflozin 10 mg

Empagliflozin 10 mg tablet

DRUG

Metformin 500 mg

Metformin 500 mg tablet

DRUG

Empagliflozin/Metformin FDC

12.5 mg Empagliflozin / 500 mg Metformin

Trial Locations (1)

Unknown

1276.24.001 Boehringer Ingelheim Investigational Site, Toronto

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02028767 - Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets | Biotech Hunter | Biotech Hunter